McKinsey February 13, 2025
To fully realize the potential of AI and digital, biopharma sponsors need a structured approach to upgrading tech infrastructure for efficient data capture and trial management.
Breakthroughs in scientific research and increased public and private investments have yet to negate the long timelines and rising costs of clinical trials. Such challenges continue to drag down biopharma R&D productivity and hold back innovative therapies from making it to market. Although clinical development speed increased during the COVID-19 pandemic, an increasing number of pharma candidates in the pipeline, coupled with a decreasing success rate of clinical trials, has put additional pressure on companies to maintain and even pick up the pace. This is on top of the imperative to improve the quality...
Today's Sponsors
Today's Sponsor